Phase 4
Completed N=87
A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
Glaucoma, Open-Angle · Hypertension
Source: ClinicalTrials.gov NCT02020512 ↗
Enrolled (actual)
87
Serious AEs
0.0%
Results posted
Jul 2014
Primary outcomePrimary: Change From Baseline in Intraocular Pressure (IOP) in the Study Eye — 22.2; -6.7 Millimeters of Mercury (mmHg)
Summary
This study will evaluate 0.03% bimatoprost in the treatment of primary open angle glaucoma and ocular hypertension.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Intraocular Pressure (IOP) in the Study Eye |
22.2; -6.7 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosis of open-angle glaucoma or ocular hypertension
- No use of Lumigan® in the past 3 months
Exclusion Criteria
- Received laser therapy, glaucoma surgery, cataract surgery, or other ocular surgery within the past 3 months
Data sourced from ClinicalTrials.gov (NCT02020512). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.